Related references
Note: Only part of the references are listed.Biomarkers in Lung Adenocarcinoma A Decade of Progress
Lynette M. Sholl
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review
Samuel J. Klempner et al.
CLINICAL LUNG CANCER (2015)
Genomic alterations in lung adenocarcinoma
Siddhartha Devarakonda et al.
LANCET ONCOLOGY (2015)
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status
Giulio Metro et al.
CLINICAL LUNG CANCER (2014)
Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
Nobuaki Ochi et al.
EXPERIMENTAL CELL RESEARCH (2014)
pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner
Ranadip Mandal et al.
MOLECULAR ONCOLOGY (2014)
The clinical development of MEK inhibitors
Yujie Zhao et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Prognostic and predictive biomarkers in lung cancer. A review
Erik Thunnissen et al.
VIRCHOWS ARCHIV (2014)
Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors
Gang Zheng et al.
ACTA CYTOLOGICA (2013)
Semi-Nested Real-Time Reverse Transcription Polymerase Chain Reaction Methods for the Successful Quantitation of Cytokeratin mRNA Expression Levels for the Subtyping of Non-Small-Cell Lung Carcinoma Using Paraffin-Embedded and Microdissected Lung Biopsy Specimens
Yoko Nakanishi et al.
ACTA HISTOCHEMICA ET CYTOCHEMICA (2013)
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
Melissa L. Johnson et al.
CANCER (2013)
Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies
Dong M. Shin et al.
CLINICAL CANCER RESEARCH (2013)
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
Stephanie Cardarella et al.
CLINICAL CANCER RESEARCH (2013)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Genetics and biomarkers in personalisation of lung cancer treatment
Rafael Rosell et al.
LANCET (2013)
Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry
Gou Mizutani et al.
ACTA HISTOCHEMICA ET CYTOCHEMICA (2012)
Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas
Makoto Sonobe et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA
Tomomi Nakamura et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
New driver mutations in non-small-cell lung cancer
William Pao et al.
LANCET ONCOLOGY (2011)
Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation
Yuji Kubota et al.
NATURE CELL BIOLOGY (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell et al.
ONCOTARGET (2011)
Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer
Jer-Yen Yang et al.
CANCER RESEARCH (2010)
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies
Stig Linder et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2010)
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
John D. Hainsworth et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Fully Integrated and Automated Detection System for Single Nucleotide Polymorphisms of UGT1A1 and CYP2C19
Norio Ureshino et al.
ONCOLOGY RESEARCH (2010)
Activation of the MEK-S6 Pathway in High-grade Ovarian Cancers
Aviva P. Ventura et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2009)
MAPK signaling pathways in the regulation of hematopoiesis
Christian R. Geest et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2008)
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics
Mark S. Cragg et al.
PLOS MEDICINE (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
MAP kinase pathways: The first twenty years
Joseph Avruch
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
A translational view of the molecular pathogenesis of lung cancer
Mitsuo Sato et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Update on epidermal growth factor receptor mutations in non-small cell lung cancer
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2006)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
p63 is the molecular switch for initiation of an epithelial stratification program
MI Koster et al.
GENES & DEVELOPMENT (2004)
Sex steroid hormone receptors in human thymoma
H Ishibashi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Proliferation of cancer cells despite CDK2 inhibition
O Tetsu et al.
CANCER CELL (2003)
Share Paper
